Over the past four weeks, Boston Scientific shares have declined by 6.3%, driving the relative strength index into oversold territory for the first time since mid-2024. This technical setup suggests that recent selling pressure may have reached an extreme, creating a higher probability of a bounce once short-term sellers cover their positions. Daily trading volumes over the last ten sessions have averaged 20% above the 30-day norm, indicating that institutional participants have been active in the sell-off, which often precedes a corrective rally when sentiment shifts.

In December, Boston Scientific agreed to acquire thrombectomy specialist Penumbra for $14.5 billion in a cash-and-stock transaction, with shareholders receiving roughly 73% cash and 27% equity. Penumbra’s preliminary fourth-quarter results showed revenue growth between 21% and 24%, driven by strong demand for its neuro and peripheral thrombectomy systems. Management forecasts a first-year earnings dilution of approximately 6 to 8 cents per share, with accretion anticipated in year two as cost synergies and cross-selling opportunities materialize.

Over the past month, 14 out of 18 Wall Street analysts have raised full-year 2026 earnings projections for Boston Scientific, boosting consensus estimates by an average of 4.7%. The upgrade trend culminated with Citigroup’s shift to a Buy recommendation following the company’s presentation at the J.P. Morgan Healthcare Conference, where leadership highlighted margin expansion in its electrophysiology and WATCHMAN franchises. Analysts cite the shift toward higher-growth, higher-margin product lines as the primary catalyst underpinning improved earnings quality and cash flow stability.